

DRAFT

February ____, 2007

Via U.S. MAIL

Richard Irons, PhD, DABT
Principal Investigator, Shanghai Health Study
University of Colorado Health Sciences Center
4200 East 9th Avenue, C238
Denver, CO 80262

Re: *Supplemental Funding for Shanghai Study*

Dear Dr. Irons:

I am writing on behalf of the Benzene Health Research Consortium (“BHRC”), the group of companies supporting the scientific and clinical research you are conducting in China. We appreciate your serving as a principal investigator for this unique project in Shanghai. We have considered your request for additional support, and are pleased to report that we are prepared to offer additional funding, in the amount of \$6,559,864. **[CORRECT AMOUNT?]**

We assume the substantive provisions of our original agreement will be a part of any subsequent contracts necessary to enable completion of the study. We are also providing separate and additional funding for QA/QC, as was outlined in your original proposal. As you have suggested, Dr. Jerry Rice, chair of the Scientific Review Panel for the study, as well as other colleagues, have agreed to assist in this effort. We assume the supplemental QA/QC plan, as developed by you and the Data Process Quality Assurance team, whose charter is attached, will be implemented. Please contact us if either of our assumptions are not correct.

We would also appreciate receiving a contract proposal from CinPathoGen, as well as its agreements with the University of Colorado and Fudan University. Please forward at your earliest convenience. It will be necessary to have all the agreements executed and in place before the actual disbursement of funds begins. We know the additional funding is time-sensitive, and we will do what we can to expedite it.

Sincerely yours,

Jennifer B. Galvin, Ph.D., DABT, CIH
Chair, Technical Committee
Shanghai Health Study

To: Clegg, Patsy M SCC-DCS/22 <patsy.clegg@shell.com>
From: stephen.m.bowes@exxonmobil.com <stephen.m.bowes@exxonmobil.com>
Cc: brian.e.doll@exxonmobil.com <brian.e.doll@exxonmobil.com>
Bcc:
Received Date: 2007-02-14 20:52:46 GMT
Subject: Re: BHRC draft letter to Irons for review and response by cob Feb 14

Patsy,

ExxonMobil approves.

Regards,

Stephen Bowes
ExxonMobil Biomedical Sciences, Inc.
Tel: (703) 846-1199....Fax: (703) 846-5297....Pager (732) 437-0999

<patsy.clegg@s
hell.com>

To
<brian.e.doll@exxonmobil.com>,
02/14/07 12:17 PM <jarnotb@api.org>,
<burnetdm@bp.com>,
<Mike.d.Johnston@ConocoPhillips.com>
, <whiter@api.org>,
<stuart.cagen@shell.com>,
<ZachWong@chevrontexaco.com>,
<anita.balaraman@chevrontexaco.com>,
<jennifer.b.galvin@conocophillips.co
m>, <hughm7@BP.com>,
<michael.g.bird@exxonmobil.com>,
<Shan.Tsai@shell.com>,
<stephen.m.bowes@exxonmobil.com>,
<alex.yelland@chevron.com>,
<myron.c.harrison@exxonmobil.com>,
<heroldra@bp.com>,
<trisha.m.perkins@exxonmobil.com>,
<wagner@api.org>,
<mfitzsim@steptoe.com>

cc

Subject
BHRC draft letter to Irons for
review and response by cob Feb 14

Regards,
Patsy

Patsy Clegg
Product Steward, HSSE
Shell Chemical LP
One Shell Plaza, 910 Louisiana, Houston, TX 77002-4916

Tel: +1 713 241 2521 Fax: 3325
Email: patsy.clegg@shell.com
Internet: <http://www.shell.com/chemicals>

Business Success through HSSE Excellence
<<API_ Alternative Ltr to Rlrons re Shanghai Health Study (2).ZIP>>
(See attached file: API_ Alternative Ltr to Rlrons re Shanghai Health Study
(2).ZIP)

Attachments:

API_ Alternative Ltr to Rlrons re Shanghai Health Study (2).ZIP

DRAFT

February _____, 2007

Via U.S. MAIL

Richard Irons, PhD, DABT
Principal Investigator, Shanghai Health Study
University of Colorado Health Sciences Center
4200 East 9th Avenue, C238
Denver, CO 80262

Re: ***Supplemental Funding for Shanghai Health Study***

Dear Dr. Irons:

I am writing on behalf of the Benzene Health Research Consortium (“BHRC”), the group of companies supporting the scientific and clinical research you are conducting in China, Shanghai Health Study. We appreciate your serving as a principal investigator for this unique project in Shanghai. We have considered your request for additional support, and are pleased to report that we are prepared to offer additional funding, in the amount of \$6,559,864. It will be necessary to have agreements executed and in place before the actual commitment is finalized and disbursement of funds begins. **[CORRECT AMOUNT?]**

We assume the substantive provisions of our original agreement will be a part of subsequent contracts necessary to enable completion of the study. We are also providing separate and additional funding for QA/QC, as was outlined in your original proposal. As you have suggested, Dr. Jerry Rice, chair of the Scientific Review Panel for the study, as well as other colleagues, have agreed to assist in this effort. We assume the supplemental QA/QC plan, as developed by you and the Data Process Quality Assurance team, whose charter is attached, will be implemented. Please contact us if either of our assumptions is not correct.

We would also appreciate receiving your contract proposal, as well as agreements with the University of Colorado and Fudan University. Please forward at your earliest convenience. We know the additional funding is time-sensitive, and we will do what we can to expedite it.

Sincerely yours,

Jennifer B. Galvin, Ph.D., DABT, CIH
Chair, Technical Committee
Shanghai Health Study